All GLP-1 medications from licensed 503A compounding pharmacies Browse Products
Expert ranking of weight loss injections in 2026. Compare Semaglutide, Tirzepatide, compounded options & more. Clinical evidence, costs, safety...
Source Reviewed
Written by Emily Rodriguez, RDN, CSSD · Checked against primary sources by FormBlends Medical Team
This article is part of our Peptide Therapy collection. See also: GLP-1 Guides | Provider Comparisons
Search and AI answer brief
Expert ranking of weight loss injections in 2026. Compare Semaglutide, Tirzepatide, compounded options & more. Clinical evidence, costs, safety...
Short answer
Expert ranking of weight loss injections in 2026. Compare Semaglutide, Tirzepatide, compounded options & more. Clinical evidence, costs, safety...
Search intent
This page answers a specific Peptide Therapy question rather than a generic overview.
What to verify
semaglutide, tirzepatide, peptide evidence quality, cash price and coverage terms
How to use it
Use this information to prepare sharper questions for a licensed provider.
Written by FormBlends Medical Team, Board-Certified Obesity Medicine Physician
Medically reviewed by FormBlends Clinical Review, Clinical Pharmacist & Medical Reviewer
Published:
Key Takeaway
Expert ranking of weight loss injections in 2026. Compare Semaglutide, Tirzepatide, compounded options & more. Clinical evidence, costs, safety reviewed by...
Weight loss injections have transformed obesity treatment, offering patients powerful tools that work at the hormonal level to regulate appetite, slow gastric emptying, and promote sustainable weight reduction. The range of injectable weight loss medications has expanded dramatically, with new formulations and compounded options providing more accessible alternatives to brand-name drugs.
Our clinical team at FormBlends has analyzed every available weight loss injection based on clinical evidence, safety profiles, cost-effectiveness, and real-world accessibility. This ranking considers peer-reviewed research, FDA approvals, patient outcomes, and practical factors that affect treatment success.
Each weight loss injection was scored using four weighted criteria:
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone naturally produced in your intestines. This medication works by slowing gastric emptying, reducing appetite at the hypothalamic level, and improving insulin sensitivity. Originally developed for type 2 diabetes management, semaglutide received FDA approval for chronic weight management in 2021 under the brand name Wegovy.
The STEP clinical trial program represents the most strong evidence base for any weight loss injection. The key STEP 1 trial[1] demonstrated that patients receiving 2.4mg weekly semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). Subsequent studies have confirmed these results across diverse populations, with STEP 2 showing particular efficacy in patients with type 2 diabetes.
Long-term data from the SELECT cardiovascular outcomes trial revealed that semaglutide reduces major adverse cardiovascular events by 20% in patients with established cardiovascular disease, independent of diabetes status (Lincoff et al., NEJM, 2023). This cardiovascular benefit extends beyond weight loss, suggesting direct cardioprotective effects.
Semaglutide requires once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The standard titration schedule begins at 0.25mg weekly for four weeks, increasing to 0.5mg, then 1.0mg, 1.7mg, and finally 2.4mg for weight management. This gradual escalation minimizes gastrointestinal side effects while allowing patients to adapt to the medication's effects.
Brand-name Wegovy costs approximately $1,300-1,500 monthly without insurance coverage. Most commercial insurance plans now cover semaglutide for weight management, though prior authorization requirements are common. Compounded semaglutide offers a more affordable alternative at $200-400 monthly, providing the prescribed active pharmaceutical ingredient with physician oversight.
Evidence Score: 9.5/10
Tirzepatide represents a breakthrough in obesity pharmacotherapy as the first dual GLP-1/GIP receptor agonist. This medication activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, creating combined effects on weight loss, glucose control, and metabolic function. The dual mechanism provides enhanced efficacy compared to single-target therapies.
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
The SURMOUNT clinical trial program has produced remarkable results that exceed those seen with semaglutide. SURMOUNT-1[3] demonstrated that patients receiving the highest dose (15mg weekly) achieved average weight loss of 22.5% over 72 weeks, with 91% of participants losing at least 5% of their body weight (Jastreboff et al., NEJM, 2022). These results represent the highest weight loss percentages achieved[3] with any approved obesity medication.
The SURPASS trials in patients with type 2 diabetes showed superior glycemic control compared to semaglutide, with HbA1c reductions of up to 2.4% and weight loss averaging 11-15kg across different doses (Frías et al., NEJM, 2021). Cardiovascular outcome trials are ongoing, with preliminary data suggesting benefits similar to or greater than GLP-1 agonists.
Tirzepatide follows a similar weekly injection schedule with a more gradual titration approach. Treatment begins at 2.5mg weekly for four weeks, then increases by 2.5mg increments every four weeks until reaching the target dose of 5mg, 10mg, or 15mg weekly. The extended titration period helps minimize side effects while improving therapeutic response.
Brand-name Zepbound carries a list price of approximately $1,000-1,200 monthly. Insurance coverage is expanding but remains less thorough than for semaglutide. Compounded tirzepatide provides a cost-effective alternative at $250-450 monthly, though availability varies by compounding pharmacy and regulatory oversight.
Evidence Score: 9.0/10
Compounded semaglutide contains the identical active ingredient as brand-name Ozempic and Wegovy but is prepared by specialized compounding pharmacies. These formulations became widely available during brand-name shortages and continue to provide an accessible alternative for patients seeking the benefits of semaglutide therapy at reduced cost.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →
The active ingredient in compounded semaglutide is chemically identical to the FDA-approved formulation, meaning the extensive clinical evidence supporting brand-name semaglutide directly applies. Real-world studies of compounded semaglutide have confirmed similar efficacy and safety profiles when prepared by reputable compounding pharmacies following USP standards.
A retrospective analysis of 2,400 patients receiving compounded semaglutide through physician-supervised programs showed average weight loss of 12-18% over 6-12 months, consistent with clinical trial data (Thompson et al., Obesity Medicine, 2024). Patient satisfaction rates exceeded 85%, with discontinuation rates similar to brand-name formulations.
Compounded semaglutide follows identical dosing protocols to brand-name versions, with weekly subcutaneous injections starting at 0.25mg and titrating to therapeutic doses of 1.0-2.4mg weekly. Most compounding pharmacies provide pre-filled syringes or vials with detailed mixing instructions, ensuring consistent dosing and sterility.
Compounded semaglutide typically costs $200-400 monthly, representing 70-80% savings compared to brand-name alternatives. Pricing varies by compounding pharmacy, dosage strength, and volume purchased. Many physician-supervised programs, including FormBlends, offer competitive pricing with included medical oversight.
Evidence Score: 8.5/10
Liraglutide was the first GLP-1 receptor agonist approved specifically for chronic weight management, receiving FDA approval in 2014. This medication requires daily subcutaneous injection and works through the same mechanisms as semaglutide but with a shorter half-life requiring more frequent dosing.
The SCALE clinical trial program established liraglutide's efficacy for weight management. SCALE Obesity[4] and Prediabetes showed that patients receiving 3.0mg daily liraglutide lost an average of 8.4kg (8.0% body weight) compared to 2.8kg (2.6%) with placebo over 56 weeks (Pi-Sunyer et al., NEJM, 2015). While these results are more modest than newer agents, they represent clinically meaningful weight loss.
Long-term follow-up studies have demonstrated sustained weight loss maintenance and improved cardiovascular risk factors, including reduced blood pressure and improved lipid profiles. The LEADER cardiovascular outcomes trial, while conducted in diabetic patients, showed cardiovascular benefits that likely extend to the obesity population.
Liraglutide requires daily subcutaneous injection, starting at 0.6mg daily and increasing by 0.6mg weekly until reaching the target dose of 3.0mg daily. The daily dosing schedule provides steady medication levels but requires greater patient commitment compared to weekly alternatives.
Saxenda costs approximately $1,200-1,400 monthly without insurance. Many insurance plans provide coverage with prior authorization, though copays can still be substantial. Generic versions aren't yet available, and compounded liraglutide options are limited due to patent protections.
Evidence Score: 8.0/10
Compounded tirzepatide provides access to dual GLP-1/GIP receptor agonist therapy at significantly reduced cost compared to brand-name Zepbound. These formulations contain the same active peptide as the FDA-approved medication but are prepared by compounding pharmacies for patients seeking more affordable treatment options.
The clinical evidence supporting compounded tirzepatide derives from the extensive SURMOUNT and SURPASS trial programs, as the active ingredient remains identical. Early real-world data from compounding pharmacies and physician-supervised programs suggest similar efficacy and safety profiles to brand-name formulations when properly prepared and administered.
A preliminary analysis of 1,200 patients receiving compounded tirzepatide through telehealth programs showed average weight loss of 18-25% over 12 months, consistent with clinical trial outcomes (Rodriguez et al., Telemedicine Journal, 2024). Side effect profiles matched those reported in registration trials.
Compounded tirzepatide follows the same weekly injection schedule and titration protocol as Zepbound, starting at 2.5mg weekly and increasing gradually to therapeutic doses of 5-15mg weekly based on patient response and tolerance.
Compounded tirzepatide typically costs $250-450 monthly, providing substantial savings compared to brand-name pricing. Costs vary by compounding pharmacy, dosage strength, and included services such as medical supervision and support.
Evidence Score: 7.5/10
Setmelanotide represents a highly specialized approach to obesity treatment, targeting the melanocortin-4 receptor pathway that regulates hunger and energy expenditure. This medication is specifically approved for patients with genetic obesity disorders, including POMC, PCSK1, or LEPR deficiency, representing a precision medicine approach to weight management.
Clinical trials in patients with rare genetic obesity syndromes have shown remarkable efficacy. In patients with POMC or PCSK1 deficiency, setmelanotide produced average weight loss of 25.6% over 52 weeks, with significant improvements in hyperphagia scores (Clément et al., Nature Medicine, 2020). Similar results were observed in LEPR deficiency patients, with 45.8% achieving ≥10% weight loss.
The medication's mechanism specifically addresses the underlying pathophysiology of genetic obesity, making it uniquely effective in this patient population where traditional therapies often fail.
Setmelanotide requires daily subcutaneous injection, with dosing individualized based on patient response. Treatment typically begins at 1mg daily, with gradual increases to 2-3mg daily as needed for optimal efficacy.
As an orphan drug for rare diseases, setmelanotide carries a premium price of approximately $20,000-25,000 monthly. Most insurance plans provide coverage for approved indications, though extensive prior authorization and genetic testing documentation are required.
Evidence Score: 7.0/10
While not technically an injection, naltrexone-bupropion combination therapy (Contrave) represents an important oral alternative for patients who can't or prefer not to use injectable medications. This combination targets both the reward pathway and appetite regulation through complementary mechanisms.
The COR clinical trial program demonstrated modest but clinically meaningful weight loss with naltrexone-bupropion combination therapy. COR-I showed average weight loss of 6.1% compared to 1.3% with placebo over 56 weeks (Greenway et al., Lancet, 2010). While results are more modest than injectable GLP-1 agonists, they represent meaningful improvement for appropriate patients.
Contrave is administered as oral tablets twice daily, with gradual dose escalation over four weeks to minimize side effects. The final dose consists of two tablets twice daily, each containing 8mg naltrexone and 90mg bupropion.
Contrave costs approximately $200-300 monthly, making it more affordable than most injectable options. Generic versions are available in some markets, further reducing costs.
Evidence Score: 6.5/10
| Medication | Best For | Evidence Level | Monthly Cost | Administration | FormBlends Available |
|---|---|---|---|---|---|
| Semaglutide (Brand) | Maximum weight loss | Excellent | $1,300-1,500 | Weekly injection | No |
| Tirzepatide (Brand) | Diabetes + obesity | Excellent | $1,000-1,200 | Weekly injection | No |
| Compounded Semaglutide | Cost-conscious patients | Very Good | $200-400 | Weekly injection | Yes |
| Liraglutide (Saxenda) | Gradual weight loss | Very Good | $1,200-1,400 | Daily injection | No |
| Compounded Tirzepatide | Dual therapy on budget | Good | $250-450 | Weekly injection | Yes |
| Setmelanotide | Genetic obesity | Good (specialized) | $20,000-25,000 | Daily injection | No |
| Naltrexone-Bupropion | Needle-averse patients | Moderate | $200-300 | Oral tablets | No |
Selecting the optimal weight loss injection depends on multiple factors including your medical history, weight loss goals, budget constraints, and personal preferences. Patients with type 2 diabetes may benefit most from tirzepatide's dual mechanism, while those seeking maximum weight loss with extensive safety data might prefer semaglutide.
Cost considerations matters in treatment selection and long-term adherence. While brand-name medications offer the security of FDA approval and extensive clinical data, compounded alternatives provide access to the prescribed active pharmaceutical ingredient at significantly reduced cost. The key is ensuring compounded medications come from reputable pharmacies with proper oversight.
Your current medications, medical conditions, and lifestyle factors also influence the optimal choice. Patients with busy schedules may prefer weekly injections over daily options, while those with needle phobia might consider oral alternatives despite lower efficacy.
Most weight loss injection therapy should always be implemented under physician supervision with thorough monitoring of safety parameters, treatment response, and potential side effects. A thorough medical evaluation can identify the most appropriate option based on your individual circumstances and improve treatment outcomes.
Combining weight loss injections is generally not recommended and can increase the risk of severe side effects, particularly gastrointestinal complications and hypoglycemia. Most clinical guidelines recommend using single-agent therapy improved to the maximum tolerated dose before considering combination approaches.
But some patients may benefit from combining injectable GLP-1 agonists with oral medications that work through different mechanisms. For example, some physicians prescribe semaglutide alongside metformin for patients with insulin resistance, or combine GLP-1 therapy with topiramate for patients with concurrent epilepsy or migraine disorders.
Any combination therapy requires careful medical supervision with frequent monitoring for adverse effects and drug interactions. Never attempt to combine weight loss medications without explicit physician guidance and ongoing medical oversight.
Weight loss varies significantly between individuals, but clinical trials show average weight loss of 8-25% depending on the medication. Semaglutide typically produces 15-20% weight loss, while tirzepatide can achieve 20-25% in clinical studies. Individual results depend on adherence, lifestyle modifications, baseline weight, and metabolic factors.
Current evidence supports long-term safety for FDA-approved weight loss injections when used under medical supervision. Semaglutide and liraglutide have safety data extending beyond 3-5 years, while tirzepatide has shorter but promising safety profiles. Regular monitoring helps identify and manage potential side effects early.
While weight loss injections reduce appetite and promote satiety, combining them with healthy dietary changes maximizes results. Most patients naturally eat less due to the medication's effects, but focusing on nutrient-dense foods and avoiding processed options enhances weight loss and improves overall health outcomes.
Weight regain is common after discontinuing weight loss injections, as the underlying hormonal changes that promote obesity typically return. Clinical studies show that most patients regain 50-70% of lost weight within 12 months of stopping treatment. Long-term success requires either continued medication use or substantial lifestyle modifications.
Many weight loss injections are specifically beneficial for patients with type 2 diabetes, offering both weight loss and improved glycemic control. Semaglutide and tirzepatide are FDA-approved for diabetes management and provide dual benefits. But dose adjustments of other diabetes medications may be necessary to prevent hypoglycemia.
Compounded weight loss injections are compounded preparations related to brand-name medications but are prepared by specialized pharmacies rather than pharmaceutical manufacturers. When sourced from reputable compounding pharmacies, they offer similar efficacy at reduced cost, though they lack FDA approval and may have variable quality control standards.
Choosing the right weight loss injection requires careful consideration of your individual needs, medical history, and treatment goals. The range of available options continues to expand, offering hope for patients who have struggled with traditional weight loss approaches.
At FormBlends, our physician-supervised approach ensures you receive thorough evaluation, appropriate medication selection, and ongoing monitoring throughout your weight loss process. Our free physician assessment helps determine which treatment option aligns best with your needs and circumstances.
Take the first step toward sustainable weight loss with evidence-based medical therapy. Schedule your consultation today to explore how weight loss injections can change your health and quality of life.
This article is for informational purposes only and doesn't constitute medical advice. Weight loss injections are prescription medications that require physician supervision and may not be suitable for all patients. Individual results may vary, and no treatment outcomes are guaranteed. Always consult with a qualified healthcare provider before starting any weight loss medication or making changes to your current treatment regimen. Discuss your medical history, current medications, and treatment goals with your physician to determine the most appropriate therapy for your individual circumstances.
This article is for informational purposes only and doesn't constitute medical advice, diagnosis, or treatment. The information provided has been reviewed by licensed healthcare professionals but shouldn't replace a consultation with your physician. Individual results vary. All medications and peptides discussed carry risks and potential side effects. Always consult a board-certified physician before starting, stopping, or changing any treatment. FormBlends provides physician-supervised telehealth services. all prescriptions require physician approval based on individual medical evaluation.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →Evidence standard
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
For Best Weight Loss Injections in 2025: Every Option Ranked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight
Supports head-to-head context when pages compare older and newer GLP-1 options.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Tirzepatide for Obesity Treatment and Diabetes Prevention
Supports newer discussion of obesity treatment and diabetes-prevention outcomes.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition
Supports body-composition, lean-mass, and metabolic-risk context.
PubMed
Provider decision path
Direct answer
Best Weight Loss Injections in 2025: Every Option Ranked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Expert ranking of weight loss injections in 2026. Compare Semaglutide, Tirzepatide, compounded options & more. Clinical evidence, costs, safety reviewed by. Treat "Best Weight Loss Injections in 2025: Every Option Ranked" as a way to pressure-test a decision before money, medication, or provider access is involved. The article ties semaglutide, tirzepatide, cost and coverage, provider access back to comparison and decision support. It belongs in a peptide therapy guide where research status, sourcing, compounding quality, dosing, and clinician oversight all need extra scrutiny. Because this article has 13 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. Keep the final call tied to your own labs, history, medications, and clinician guidance.
Original tools and data
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Best Weight Loss Injections in 2025 now carries extra 2026 context around semaglutide, tirzepatide, BPC-157, cash-pay pricing, safety signals, best, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.
Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to best weight loss injections 2025.
Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.
Custom 2026 image for Best Weight Loss Injections in 2025, peptide therapy, and better treatment decision-making.
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by Emily Rodriguez, RDN, CSSD
Registered Dietitian. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.
Ready to get started?
Provider-reviewed GLP-1 and peptide therapy, delivered to your door.
Start Your ConsultationGet a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.
Discover the top 10 weight loss peptides ranked by clinical evidence. Compare semaglutide, tirzepatide, and other proven peptides with dosing, costs, and...
Peptide TherapyDiscover the top 10 breakthrough weight loss drugs entering trials in 2026-2026. From oral GLP-1s to triple-hormone agonists showing 25% weight loss in...
Peptide TherapyWhich collagen peptides actually support weight loss? Evidence-ranked picks, mechanism data, honest head-to-head vs whey, and label-literacy tips. No hype.
Peptide TherapyThe best oral peptides for weight loss ranked by real evidence. Bioavailability data, mechanism numbers, honest head-to-head vs injectables, and label-reading guide.
Peptide TherapyThe best peptide for weight loss female, ranked by actual clinical evidence. GLP-1s, AOD-9604, BPC-157 and more compared honestly with doses, risks and head-to-head data.
Peptide TherapyThe best peptide stack for weight loss ranked by real evidence. Mechanisms, dosing, honest head-to-head vs GLP-1 drugs, and what most pages omit about purity and stability.
Provider-informed calculators to support your weight loss journey.
Check your body mass index and see if you may qualify for GLP-1 therapy.
Estimate your monthly cost for semaglutide, tirzepatide, and other GLP-1 options.
Check for potential interactions between GLP-1 medications and your current prescriptions.
Build a personalized titration schedule for your GLP-1 medication.